Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Aclaris Therapeutics, Inc. (ACRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $357.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $173.00K.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $184.00K.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $266.00K, a 72.73% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-12-31 was $154.00K, a 2980.00% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $285.00K, a 39.75% decline from fiscal 2023.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $473.00K, a 57.77% decline from fiscal 2022.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.12M, a 18.43% decline from fiscal 2021.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $1.37M, a 846.90% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $173.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $357.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $184.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $266.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $285.00K 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $19.00K 10-Q · filed 2024-11-06 | |||
| 2023-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $473.00K 10-K · filed 2025-02-27 | ||
| 2023-09-30 | $319.00K 10-Q · filed 2023-11-06 | |||
| 2022-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $5.00K derived: sum of 2 quarters · filed 2024-02-27 | $644.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.12M 10-K · filed 2024-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $639.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.11M 10-Q · filed 2022-11-08 | $1.11M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $639.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.11M 10-Q · filed 2022-08-03 | $1.11M derived: sum of 3 quarters · filed 2024-02-27 | $1.11M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $476.00K 10-Q · filed 2022-05-10 | $476.00K derived: sum of 2 quarters · filed 2024-02-27 | $476.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.63M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $1.15M derived: sum of 3 quarters · filed 2024-02-27 | $1.37M 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $1.15M derived: sum of 2 quarters · filed 2021-11-02 | $1.37M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.37M 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | $224.00K 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $145.00K 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $112.00K 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $724.00K 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |